Sugi Predict

Sugi Predict / Compounds / SCHEMBL19963552

SCHEMBL19963552

SCHEMBL19963552

CCC(=O)COCCCCCN(C)C(C)C

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 2/20 0.40
▸ SPHK1 Q9NYA1 1/20 0.34
▸ PLA2G4B P0C869 3/20 0.33
▸ NR1I2 O75469 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ DRD1 P21728 1/20 0.33
▸ TBXA2R P21731 1/20 0.33
▸ AGTR1 P30556 1/20 0.33
▸ PTGIR P43119 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ PTGDR Q13258 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.31
▸ NAAA Q02083 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20325687 0.90 CES2 (0.33) CES2ALDH1A1
SCHEMBL19963644 0.83 CES2 (0.55) CES2SPHK1NR1I2ADORA3DRD1
SCHEMBL21026058 0.83 ALDH1A1 (0.35) ALDH1A1
SCHEMBL17169730 0.82 CES2 (0.37) CES2SPHK1NR1I2ADORA3DRD1
SCHEMBL23897295 0.81 CES2 (0.36) CES2SPHK1NR1I2ADORA3DRD1
SCHEMBL20206397 0.80 CES2 (0.42) CES2PLA2G4BNAAA
SCHEMBL24477437 0.77 SPHK1 (0.37) SPHK1ALDH1A1
SCHEMBL23308133 0.77 SPHK1 (0.37) SPHK1ALDH1A1
SCHEMBL23308135 0.75 SPHK1 (0.47) CES2SPHK1ALDH1A1
SCHEMBL23308047 0.75 SPHK1 (0.40) CES2SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2023-06-15 — — US disclosed
US-20220387411-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS VULCAN BIO CORPORATION 2022-12-08 — — US disclosed
US-11161841-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2021-11-02 — — US disclosed
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-10-07 — — US disclosed
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2021-07-20 — — US disclosed
US-20210145832-A1 TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2021-05-20 — — US disclosed
US-20200155690-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2020-05-21 — — US disclosed
US-20190315732-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2019-10-17 — — US disclosed
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES ARVINAS OPERATIONS, INC. 2019-05-23 — — US disclosed
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2018-08-02 — — US disclosed
US-20180072711-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ARVINAS OPERATIONS, INC. 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES IRAK1, IRAK4, IRAK2 CES2 4048/4885SPHK1 1782/4885PLA2G4B 2402/4885
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 CES2 2381/4885SPHK1 4485/4885PLA2G4B 1746/4885
US-20220387411-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS ATG7, BECN1, SQSTM1 CES2 2893/4885SPHK1 2518/4885PLA2G4B 2665/4885
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 CES2 4048/4885SPHK1 1782/4885PLA2G4B 2402/4885
US-20180072711-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESR1, GPER1, ESR2 CES2 1038/4885SPHK1 2807/4885PLA2G4B 1532/4885
US-20210145832-A1 TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE TBK1, TNKS, TBKBP1 CES2 4328/4885SPHK1 2076/4885PLA2G4B 2662/4885
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF VHL, MDM2, CUL2 CES2 4234/4885SPHK1 4671/4885PLA2G4B 3672/4885
US-20190315732-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE MDM2, CRBN, VHL CES2 3114/4885SPHK1 3979/4885PLA2G4B 935/4885
US-20200155690-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 CES2 2381/4885SPHK1 4485/4885PLA2G4B 1746/4885
US-11161841-B2 Modulators of proteolysis and associated methods of use MDM2, CRBN, VHL CES2 3114/4885SPHK1 3979/4885PLA2G4B 935/4885
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 CES2 2381/4885SPHK1 4485/4885PLA2G4B 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.